News & Updates
Two hepatitis C medications, Harvoni® and Viekira Pak® were recently approved by the US Food and Drug Administration (FDA). Both medications are highly effective when used in patients with appropriate genotypes. Both have very acceptable adverse event profiles. However, both are very costly. To assure access to these and other hepatitis C medications within an affordable pharmacy benefit, UHC is pleased to announce their Prescription Drug List (PDL) decisions that will result in no negative member impact upon the February 1, 2015, implementation.
While prior authorization (and medical necessity if applicable) has been in effect since the launch of these medications to ensure appropriate coverage review and utilization, the following changes will take effect on February 1, 2015, and July 1, 2015.
February 1, 2015 (existing users grandfathered)
July 1, 2015 (January 1, 2016 for those on Traditional PDL)
UHC is happy to offer two Tier 2 options to cover all spectrums of the hepatitis C genotypes. Harvoni, the most prescribed drug because of its convenience, high effective rates and minimal side effects, will be an affordable option for members.
View a summary of all of the hepatitis C PDL decisions.
For questions, please contact a member of your b&p Sales Team - 888.722.3373.